Using ST2 in Cardiovascular Patients: A Review
- 1 July 2014
- journal article
- review article
- Published by Taylor & Francis in Future Cardiology
- Vol. 10 (4) , 525-539
Abstract
Biomarkers have emerged as indispensable tools for diagnosis and prognostication in a variety of cardiovascular diseases, and several are now standard of care. New markers are constantly being developed, but few are able to significantly improve upon already established markers. ST2 is a marker of cardiomyocyte stress and fibrosis, which provides incremental value to natriuretic peptides for risk stratification of patients across a wide spectrum of cardiovascular diseases. Based upon the totality of data, measurement of ST2 is now recommended for additive risk stratification in patients with acute or ambulatory heart failure in the 2013 American College of Cardiology Foundation and American Heart Association joint guidelines. Looking forward, ST2 levels may be useful for tailoring medical therapy in those with or at risk for developing heart failure. This paper provides an up-to-date overview of the clinical studies that led to the endorsement of ST2 as a cardiovascular prognostic marker, and provides insight into the application of ST2 now and in the future.Keywords
This publication has 53 references indexed in Scilit:
- Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β-Blocker Therapy in Chronic Heart FailureCirculation: Heart Failure, 2013
- Soluble ST2 in Ambulatory Patients With Heart FailureCirculation: Heart Failure, 2013
- Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional AssessmentMayo Clinic Proceedings, 2013
- Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart FailureCardiology, 2012
- Soluble ST2 is Associated with Adverse Outcome in Patients with Heart Failure of Ischaemic AetiologyEuropean Journal of Heart Failure, 2012
- Combined Use of High-Sensitivity ST2 and NTproBNP to Improve the Prediction of Death in Heart FailureEuropean Journal of Heart Failure, 2012
- Soluble ST2, High-Sensitivity Troponin T- and N-Terminal Pro-B-Type Natriuretic Peptide: Complementary Role for Risk Stratification in Acutely Decompensated Heart FailureEuropean Journal of Heart Failure, 2011
- High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart FailureCirculation: Heart Failure, 2011
- La monitorización de ST2 soluble proporciona una estratificación del riesgo adicional en pacientes ambulatorios con insuficiencia cardiaca descompensadaRevista Espanola de Cardiologia, 2010
- Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart FailureJournal of Cardiac Failure, 2008